Valuation: Alkermes plc

Market Cap 7.55B 6.88B 6.34B 5.77B 10.82B 699B 11.37B 77.14B 30.66B 382B 28.33B 27.74B 1,199B P/E 2026 *
-93.3x
P/E 2027 * 85.8x
Enterprise Value 8.61B 7.84B 7.23B 6.57B 12.33B 797B 12.96B 87.95B 34.96B 435B 32.31B 31.62B 1,367B EV / Sales 2026 *
4.72x
EV / Sales 2027 * 4.35x
Free-Float
89.46%
Yield 2026 *
-
Yield 2027 * -
1 day-2.69%
1 week-4.44%
Current month-0.88%
1 month+1.88%
3 months-6.41%
6 months+21.53%
Current year+60.61%
1 week 44.83
Extreme 44.83
47.76
1 month 43
Extreme 43
48.3
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.22
Extreme 22.22
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Sell

Compliance Officer

-2,035 0.0012%
8/10/26 Exercice

Chief Financial Officer

22,397 0.0134%
7/10/26 Free

Director

25,237 0.0150%
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%-4.44%+59.42%+85.86% 7.55B
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average +0.06%-4.72%+30.28%+76.36% 407B
Weighted average by Cap. +0.39%-5.19%+28.09%+87.49%

Financials

2026 *2027 *
Net sales 1.82B 1.66B 1.53B 1.39B 2.61B 169B 2.75B 18.63B 7.41B 92.26B 6.84B 6.7B 290B 1.93B 1.76B 1.62B 1.47B 2.76B 179B 2.9B 19.69B 7.83B 97.52B 7.23B 7.08B 306B
Net income -84.35M -76.83M -70.79M -64.39M -121M -7.81B -127M -862M -342M -4.27B -316M -310M -13.39B 85.49M 77.86M 71.74M 65.26M 122M 7.92B 129M 873M 347M 4.32B 321M 314M 13.57B
Net Debt 1.06B 964M 888M 808M 1.52B 98.01B 1.59B 10.81B 4.3B 53.53B 3.97B 3.89B 168B 840M 765M 705M 642M 1.2B 77.82B 1.26B 8.58B 3.41B 42.5B 3.15B 3.09B 133B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
20/11/26 USD 44.94 -2.69% 1,080,914
19/11/26 USD 46.18 -1.43% 1,406,378
18/11/26 USD 46.85 +3.08% 1,408,596
17/11/26 USD 45.45 -2.32% 932,618
16/11/26 USD 46.53 -1.06% 1,051,959
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
44.94USD
Average target price
57.74USD
Spread / Average Target
+28.48%
  1. Stock Market
  2. Stocks
  3. ALKS Stock